Volume 82 | ESPE2014 | Next issue

ESPE 2014

Dublin, Ireland
18 Sep 2014 - 20 Sep 2014

Card image cap
Dublin, Ireland; 18-20 September 2014. Further information

Poster Category 2

Growth Hormone (1)

hrp0082p2-d2-422 | Growth Hormone (1) | ESPE2014

Perceptions and Expectations of Patients and their Families for the Effects of GH Treatment

Drosatou Chrysoula , Vlachopapadopoulou Elpis-Athina , Karachaliou Feneli , Petrou Vassileios , Kaloumenou Eirini , Michalakos Stefanos

Background: Children’s and parents’ expectations regarding GH therapy results have been previously assessed. However, there are limited data on children’s and adolescents perceptions of their own body size as compared with that of their age-related peers, as well as their expectations of their final stature.Objective and hypotheses: To evaluate the perceptions of GH treated children and their families for the child’s stature and to as...

hrp0082p2-d2-423 | Growth Hormone (1) | ESPE2014

Normal Onset of Clinical Puberty for Age in GH-Treated Children with Noonan Syndrome or Turner Syndrome: Data from the NordiNet® IOS and ANSWER® Program

Ross Judith , Christesen Henrik , Lee Peter , Germak John , Pedersen Birgitte Tonnes , Kotnik Primoz

Introduction: Noonan syndrome (NS) and Turner syndrome (TS) are distinct genetic disorders with similarities in phenotype, including short stature. The NordiNet® IOS and the ANSWER Program® are observational studies evaluating effectiveness and safety of GH treatment in real-world practice.Methods: The study population included children with NS or TS with puberty recordings, enrolled in NordiNet® IOS or ANS...

hrp0082p2-d2-424 | Growth Hormone (1) | ESPE2014

What Dose of hGH is Adequate as a Substitution Therapy in GH Deficient Children?

Voutetakis Antonis , Magiakou Maria-Alexandra , Dacou-Voutetakis Catherine , Chrousos George , Kanaka-Gantenbein Christina

Background: After 50 years of hGH use for GH deficient (GHD) children the definition of the adequate hGH substitution dose and response remain uncertain.Objective and hypotheses: We hypothesized that subjects with GHD caused by congenital pituitary defects constitute an ideal model for defining substitution dose of hGH. Consequently, an appropriate study group was formed and pertinent long-term data were retrospectively analyzed.Me...

hrp0082p2-d2-425 | Growth Hormone (1) | ESPE2014

Electronic Devices and Single-Dose Dispensing Systems GH are the Most Efficient and Less Loss of Drug

Diez-Lopez Ignacio , Sarasua-Miranda Ainhoa , Elizalde Miriam Miriam , Lorente-Blazquez Isabel , Minguez Cristina , Martinez-Martinez Carlos

Background: Several pharmaceutical formulations marketed GHRH, were being restricted in their choice occasions. Three display groups: single-dose, pre-filled pens/vials and electronic devices, self-injection systems. The choice may contribute to a greater or lesser adherence and a difference in the final cost of treatment (drug loss), attributable to the device itself or presentation. Presentations that require reconstitution device load, partial doses or stop in Pen contribut...

hrp0082p2-d2-426 | Growth Hormone (1) | ESPE2014

The Level and Conformation of Blood Plasma Carotenoids in GH Deficient Children After 1 Year of GH Therapy

Faassen Maria , Pankratova Maria , Shiryaeva Tatyana , Nagaeva Elena , Peterkova Valentina , Kovalenko Svetlana , Baizhumanov Adil , Parshina Evgenia , Yusipovich Alexander , Maksimov Georgy

Background: Epidemiologic studies have shown strong associations between high carotenoids levels and reduced risk of developing various forms of cancer, cardiovascular system diseases, etc.Objective and hypotheses: Carotenoids are hydrophobic substances and are contained in blood in lipoprotein particles. Their conformation depends on their molecular environment. By evaluating the conformation of carotenoids we can obtain various information about the li...

hrp0082p2-d2-427 | Growth Hormone (1) | ESPE2014

Effects and Safety of Recombinant Human GH in GH Deficient Children with Rathke Cyst

Liang Liyang , Zhang Lina , Meng Zhe , Ou Hui , He Zhanwen , Hou Lele , Li Dongfang , Li Pinggan , Luo Xiangyang

Objective: To assess the effects and safety of recombinant human GH (rhGH) in GH deficient (GHD) children with Rathke cyst.Methods: The clinical data of 12 GHD children aged from 5–12 years old, whose radiologic diagnosis showed Rathke cyst during Jan 2010–Dec 2012 in our hospital, were analyzed retrospectively. rhGH was given subcutaneously to each enrolled child with a night dose of 0.1 IU/kg six to seven times a week for 12–30 months. T...

hrp0082p2-d2-428 | Growth Hormone (1) | ESPE2014

The Interconnectivity Between GH Replacement Therapy and Subclinical Hypothyroidism on Growth Response in Children with Pituitary Dwarfism

Bodescu Ioana , Idriceanu Jeanina , Vasiliu Ioana , Manolachie Adina , Chifu Irina Oana , Crumpei Iulia , Cristea Cristina , Preda Cristina , Mogos Voichita , Vulpoi Carmen

Background: Administration of recombinant GH (rhGH) to GH-deficient children has yielded conflicting results concerning its impact on thyroid function. Data about patients developing subclinical hypothyroidism are scanty, but it is thought to be associated with impairment of metabolic profile and lower growth response.Objective: To investigate the frequency of SH in children with pituitary dwarfism treated with rhGH, as well as its influence on rhGH ther...

hrp0082p2-d2-429 | Growth Hormone (1) | ESPE2014

What Should be the Diagnosis and Management of Short Children with IGF1 Deficiency, Responding to GH Administration Despite Normal GH Secretion?

Smyczynska Joanna , Stawerska Renata , Lewinski Andrzej , Hilczer Maciej

Background: GH deficiency (GHD) is currently defined as secondary IGF1 deficiency (IGFD). In the patients with normal GH secretion and IGFD, significant increase of IGF1 during generation test excludes primary IGFD, however is not an approved indication for GH therapy.Objective and hypotheses: The aim of the study was to assess GH therapy effectiveness in children with IGFD, responding to short-term GH administration despite normal GH peak after falling ...

hrp0082p2-d2-430 | Growth Hormone (1) | ESPE2014

A Reappraisal of the Cut-Off Limits of the Peak GH Response to Stimulation Tests for the Diagnosis of GH Deficiency in Children and Adolescents

Guzzetti Chiara , Ibba Anastasia , Pilia Sabrina , Beltrami Nadia , Di Iorgi Natascia , Rollo Alessandra , Radetti Giorgio , Zucchini Stefano , Maghnie Mohamed , Cappa Marco , Loche Sandro

Background: The diagnosis of GH deficiency (GHD) in children and adolescents is classically established when GH concentrations fail to reach an arbitrary cut-off level (usually 7–10 μg/l) after at least two provocative tests (PT).Objective and hypotheses: Aim of the study was to define optimal GH cut-offs to different PT in children and adolescent with short stature.Method: This was a retrospective study in 437 subjects w...

hrp0082p2-d2-431 | Growth Hormone (1) | ESPE2014

Vitamin D Concentrations in Children with GH Deficiency During First Year of GH Treatment

Pyrzak Beata , Witkowska-Sedek Ewelina , Kucharska Anna , Sagala Magdalena , Majcher Anna

Introduction: The start of GH (rhGH) treatment in children with GH deficiency (GHD) causes a significant increase in bone turnover and increases height velocity. The increase in IGF1 concentrations during rhGH treatment is a marker of the efficiency of treatment. A significant increase in bone turnover during rhGH treatment results in an increased demand for vitamin D. It is important to determine proper supplementation doses of vitamin D in patients during catch-up growth.</p...

hrp0082p2-d2-432 | Growth Hormone (1) | ESPE2014

Growth Hormone Treatment in Children with SGA During a 5-Year Period, Assessment of Auxological Development and Insulin Resistance

Lopez-Siguero J P , Martinez-Aedo M J , Bermudez J A , Cabrinety N , Bosch J , Lechuga J L , Torralba R

Background: Treatment with GH of children born SGA allows an increase in growth velocity (GV) and improves adult height. Increased insulin resistance has been described in these patients, which reverts after interrupting GH administration. However, long-term metabolic consequences are not clearly established.Objective and hypotheses: Describe insulin resistance (HOMA-IR index) and auxological development (GV and height) in SGA children treated with GH fo...

hrp0082p2-d2-433 | Growth Hormone (1) | ESPE2014

Comparison of Measured Lean Body Mass (LBMDXA) and Estimated LBMBIA in Children with GH Deficiency

Schweizer Roland , Ziegler Julian , Frank Laura , Binder Gerhard

Background: Long standing GH deficiency (GHD) causes loss of muscle mass. DXA enables the measurement of LBMDXA but is accompanied with a potentially harmful X-ray exposition. BIA measures the electric resistance of the body which correlates with LBM. A comparison of both methods in children with GHD has not been performed yet.Aim: Calculation of a regression formula for LBM using resistance and anthropometry based on LBMDXA in chil...

hrp0082p2-d2-434 | Growth Hormone (1) | ESPE2014

Metabolic Assessment in Children with GH Deficiency Before, During, and After Human GH Replacement Therapy

Predieri Barbara , Mazzoni Silvia , Paraluppi Valentina , Patianna Viviana , Lucaccioni Laura , Madeo Simona , Bruzzi Patrizia , Iughetti Lorenzo

Background: GH has several effects on lipid and glucose homeostasis. In adults GH deficiency (GHD) has been associated to increased mortality for cardiovascular disease (CVD). In childhood few studies have investigated the effect of GHD and recombinant human GH (rhGH) therapy on metabolic parameters that may increase the risk of CVD.Objective and hypotheses: To assess changes of lipid profile, insulin-resistance indexes, and CVD risk in children and adol...